AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21970950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (PRN dosing regimen)
Number of subjects: 0
Study 21970950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (monthly treatment)
Number of subjects: 0
Study 21970950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly treatment)
Number of subjects: 0
Study 21970950 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study 18328464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBTgsh)
Number of subjects: 75
Study 18328464 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWLgsh)
Number of subjects: 75
Study 18328464 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBTgsh) and Behavioral weight loss (BWLgsh)
Number of subjects: 75
Study 16864762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 10-session, manualized, individually administered regimen added to psychiatric consultation intervention
Number of subjects: 84
Study 16864762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 84
Study 16864762 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care augmented by a psychiatric consultation intervention (Control)
Number of subjects: 84
Study 12638392 — intervention group
Group type: COMPARATOR
Intervention: Cetrorelix (CET) single doses (0.25, 0.5, or 1 mg) on cycle day 3
Number of subjects: 0
Study 12638392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) multiple doses from cycle day 3 to day 16
Number of subjects: 0
Study 11032099 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 11032099 — intervention group
Group type: COMPARATOR
Intervention: Conventional NSAIDs
Number of subjects: 0
Study 9060527 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) and racemic leucovorin (d,l‐LV)
Number of subjects: 248
Study 9060527 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) combined with the pure l-isomer of leucovorin (l‐LV)
Number of subjects: 248
Study 8181576 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose recombinant interleukin-2 via central venous access (CVA)
Number of subjects: 52
Study 8181576 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics via the CVA
Number of subjects: 52
Study 8181576 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant infusion of low dose streptokinase via the CVA
Number of subjects: 52
Study 2535983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (1500 aPTT-U/24 h)
Number of subjects: 404
Study 2535983 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (3 x 5000 IU/24 h)
Number of subjects: 404
Study 786313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 40
Study 786313 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 40
Study 31529452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilation ≥ 4 cm
Number of subjects: 732
Study 31529452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical effacement ≥ 75%
Number of subjects: 732
Study 31529452 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and examination features (including parity and gestational age)
Number of subjects: 732
Study 31369244 — intervention group
Group type: EXPERIMENTAL
Intervention: MgO thin film; film thickness of approximately 100 nm with calcination at 400‐600 °C in air
Number of subjects: 800
Study 31369244 — intervention group
Group type: COMPARATOR
Intervention: Training data set
Number of subjects: 800
Study 31369244 — intervention group
Group type: COMPARATOR
Intervention: Test data set
Number of subjects: 800
Study 26507986 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK plate
Number of subjects: 26
Study 26507986 — intervention group
Group type: COMPARATOR
Intervention: Titanium plate
Number of subjects: 26
Study 26457458 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training (WBVT)
Number of subjects: 62
Study 26457458 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 62
Study 23562364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low spinal BMD at baseline (BMD Z‐score ≤‐2 standard deviation)
Number of subjects: 80
Study 23562364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment for vertebral fractures (VF)
Number of subjects: 80
Study 23562364 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment over 18 months
Number of subjects: 80
Study 23562364 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative techniques for vertebral height loss
Number of subjects: 80
Study 23562364 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of fracture prediction factors
Number of subjects: 80
Study 22417659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) 7%
Number of subjects: 15
Study 22417659 — intervention group
Group type: COMPARATOR
Intervention: CPAP at 10 cm H(2)O
Number of subjects: 15
Study 22417659 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP + HTS
Number of subjects: 15
Study 22417659 — intervention group
Group type: COMPARATOR
Intervention: Directed coughs (control)
Number of subjects: 15
Study 19373126 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ETDRS-style (focal/grid) photocoagulation
Number of subjects: 22
Study 17509808 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention
Number of subjects: 405
Study 17509808 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study 15188160 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT screening
Number of subjects: 91999
Study 15188160 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT screening (participants who participated at least once)
Number of subjects: 91999
Study 15188160 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 91999
Study 11397602 — intervention group
Group type: EXPERIMENTAL
Intervention: Three pain assessment instruments (visual analog scale, behavior (faces) scale, pain descriptive scale)
Number of subjects: 305
Study 11397602 — intervention group
Group type: COMPARATOR
Intervention: Question 'Do you have pain?'
Number of subjects: 305
Study 9194109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Hep-B (2.5 micrograms/dose)
Number of subjects: 205
Study 9194109 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (10 micrograms/dose)
Number of subjects: 205
Study 1357927 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz cranial TENS
Number of subjects: 90
Study 1357927 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 90
Study 1357927 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study 1357927 — intervention group
Group type: COMPARATOR
Intervention: 5 Hz cranial TENS
Number of subjects: 90
Study 1357927 — intervention group
Group type: COMPARATOR
Intervention: 2000 Hz cranial TENS
Number of subjects: 90
Study 3912647 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of arginine pyroglutamate three times a day
Number of subjects: 90
Study 3912647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3912647 — intervention group
Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 90
Study 30535959 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablet (test product)
Number of subjects: 32
Study 30535959 — intervention group
Group type: COMPARATOR
Intervention: ZYTIGA® (250 mg, reference product)
Number of subjects: 32
Study 30535959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 32
Study 29171107 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report on the Pittsburgh Sleep Quality Index for the previous month
Number of subjects: 0
Study 29171107 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report on the recording night
Number of subjects: 0
Study 29171107 — intervention group
Group type: COMPARATOR
Intervention: Actigraphic measures on the recording night
Number of subjects: 0
Study 29171107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary-reported number of awakenings
Number of subjects: 0
Study 24224856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-curved instruments
Number of subjects: 24
Study 24224856 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulating instruments
Number of subjects: 24
Study 24224856 — intervention group
Group type: COMPARATOR
Intervention: Conventional straight instruments
Number of subjects: 24
Study 24224856 — intervention group
Group type: COMPARATOR
Intervention: Double-curved instruments
Number of subjects: 24
Study 23155130 — intervention group
Group type: EXPERIMENTAL
Intervention: Upwards stripping of great saphenous vein (GSV)
Number of subjects: 50
Study 23155130 — intervention group
Group type: COMPARATOR
Intervention: Downwards stripping of great saphenous vein (GSV)
Number of subjects: 50
Study 23155130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (upwards and downwards stripping)
Number of subjects: 50
Study 23662513 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 162
Study 21059213 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH1 (7.5 mg Isoleucine‐Proline‐Proline)
Number of subjects: 70
Study 21059213 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH2 (6.6 mg Methionine‐Alanine‐Proline, 2.3 mg Leucine‐Proline‐Proline, 1.8 mg IPP)
Number of subjects: 70
Study 21059213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (containing cellulose)
Number of subjects: 70
Study 17414391 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 248
Study 17414391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling pairs
Number of subjects: 248
Study 15857459 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel applied twice daily for 4 weeks
Number of subjects: 41
Study 15857459 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 41
Study 15857459 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 41
Study 12187617 — intervention group
Group type: EXPERIMENTAL
Intervention: POST - Predefined formula beverage with added carbohydrate following exercise bouts on days 1, 3, 4, and 6
Number of subjects: 10
Study 12187617 — intervention group
Group type: COMPARATOR
Intervention: CON - Placebo beverage consumed following exercise bouts on days 1, 3, 4, and 6
Number of subjects: 10
Study 9618626 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based prevention program
Number of subjects: 0
Study 7740405 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy for high-grade soft-tissue sarcomas
Number of subjects: 0
Study 7740405 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant induction chemotherapy, regional perfusion with cytostatics (± hyperthermia), externally applicated deep regional tumor hyperthermia with systemic chemotherapy
Number of subjects: 0
Study 7740405 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled adjuvant treatment of soft-tissue sarcomas with cytostatic drugs
Number of subjects: 0
Study 2179591 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal injection of insulin for 3 days
Number of subjects: 12
Study 2179591 — intervention group
Group type: COMPARATOR
Intervention: Rotating injection among arms, abdomen, and thighs for 3 days
Number of subjects: 12
Study 6102456 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine administered intravenously
Number of subjects: 12
Study 30211831 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Sulfated Dextran (LMW-DS)
Number of subjects: 24
Study 30211831 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 24
Study 27821644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg + allopurinol
Number of subjects: 610
Study 27821644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg + allopurinol
Number of subjects: 610
Study 27821644 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol alone
Number of subjects: 610
Study 25175734 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 676
Study 25175734 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 676
Study 25175734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 24038026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309
Study 24038026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 21174586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C and 400 IU natural vitamin E (RRR α tocopherol) daily from the second trimester until delivery
Number of subjects: 50
Study 21174586 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 50
Study 19247887 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 19247887 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of London's standard
Number of subjects: 0
Study 17892989 — intervention group
Group type: COMPARATOR
Intervention: Direct stenting guided with quantitative coronary angiography (group 1)
Number of subjects: 259
Study 17892989 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting guided with IVUS (group 2)
Number of subjects: 259
Study 17892989 — intervention group
Group type: COMPARATOR
Intervention: Optimal balloon angioplasty guided with IVUS (group 3)
Number of subjects: 259
Study 15457418 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal group (95 patients)
Number of subjects: 171
Study 15457418 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene group (76 patients)
Number of subjects: 171
Study 15457418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study 11578890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg with 4% lidocaine (Group I; n = 15)
Number of subjects: 46
Study 11578890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL with saline (Group 2; n = 16)
Number of subjects: 46
Study 11578890 — intervention group
Group type: COMPARATOR
Intervention: Nothing (Control; n = 15)
Number of subjects: 46
Study 9542554 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with sufentanil 10 micrograms (LD)
Number of subjects: 1000
Study 9542554 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25% with adrenaline (HD)
Number of subjects: 1000
Study 9542554 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with sufentanil (LD)
Number of subjects: 1000
Study 7842911 — intervention group
Group type: EXPERIMENTAL
Intervention: GTW+CSA+Pred
Number of subjects: 172
Study 7842911 — intervention group
Group type: COMPARATOR
Intervention: Aza+CSA+Pred
Number of subjects: 172
Study 2970361 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 0
Study 2970361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein meal
Number of subjects: 0
Study 2970361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 0
Study 31294630 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 83
Study 31650914 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless suture bridge technique (group B)
Number of subjects: 121
Study 31650914 — intervention group
Group type: COMPARATOR
Intervention: Medial knotted suture bridge technique (group A)
Number of subjects: 121
Study 28207654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty
Number of subjects: 47
Study 28207654 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 47
Study 25277645 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate and metronidazole (2-antimicrobial group)
Number of subjects: 60
Study 25277645 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (control group)
Number of subjects: 60
Study 25277645 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 60
Study 25277645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antibiotics continued (2-antimicrobial group)
Number of subjects: 60
Study 23489381 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion
Number of subjects: 107
Study 20061435 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg/d)
Number of subjects: 274
Study 20061435 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 274
Study 18550177 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 477
Study 18550177 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 477
Study 15665210 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training programme
Number of subjects: 116
Study 15665210 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal training routine)
Number of subjects: 116
Study 15665210 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training programme aimed at players with previous ankle sprains
Number of subjects: 116
Study 12947995 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy (LNIT)
Number of subjects: 0
Study 12947995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10812221 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix (new MMR vaccine)
Number of subjects: 1779
Study 10812221 — intervention group
Group type: COMPARATOR
Intervention: Triviraten (widely used MMR vaccine)
Number of subjects: 1779
Study 8888864 — intervention group
Group type: COMPARATOR
Intervention: Window size of 4-5 characters for normally sighted (NA) group
Number of subjects: 0
Study 8888864 — intervention group
Group type: EXPERIMENTAL
Intervention: Window size of 6-7 characters for visually impaired (VI) group
Number of subjects: 0
Study 1893310 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-managed instruction (faculty as tutors)
Number of subjects: 0
Study 1893310 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom course of study
Number of subjects: 0
Study 6298103 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-421
Number of subjects: 12
Study 6298103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30948273 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg once daily continuously
Number of subjects: 463
Study 30241559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-prepared PHEA equipment and drugs
Number of subjects: 23
Study 30241559 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 23
Study 26998697 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 0
Study 26998697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24481640 — intervention group
Group type: EXPERIMENTAL
Intervention: i-CEOP (intensive chemotherapy): cyclophosphamide 1,500 mg, epirubicin 150 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Number of subjects: 250
Study 24481640 — intervention group
Group type: EXPERIMENTAL
Intervention: i-CEOP (intensive chemotherapy)
Number of subjects: 250
Study 24481640 — intervention group
Group type: COMPARATOR
Intervention: s-CEOP (standard chemotherapy): cyclophosphamide 750 mg, epirubicin 75 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Number of subjects: 250
Study 24481640 — intervention group
Group type: COMPARATOR
Intervention: s-CEOP (standard chemotherapy)
Number of subjects: 250
Study 22205319 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy)
Number of subjects: 61
Study 22205319 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.9 g/d, 0.3% of daily energy)
Number of subjects: 61
Study 22205319 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI ≥25
Number of subjects: 61
Study 22205319 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI <25
Number of subjects: 61
Study 19041207 — intervention group
Group type: EXPERIMENTAL
Intervention: MR colonography (MRC) with fecal tagging
Number of subjects: 64
Study 19041207 — intervention group
Group type: EXPERIMENTAL
Intervention: MR colonography (MRC) with bowel purgation
Number of subjects: 64
Study 19041207 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 64
Study 19041207 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 64
Study 19041207 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort with contrast mixture
Number of subjects: 64
Study 19041207 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort with bowel purgation
Number of subjects: 64
Study 17726919 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 0
Study 15629822 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL)
Number of subjects: 106
Study 15629822 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL
Number of subjects: 106
Study 12197367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 501
Study 12197367 — intervention group
Group type: COMPARATOR
Intervention: CEE-MPA (conjugated equine oestrogens 0.625 mg + medroxyprogesterone acetate 5 mg)
Number of subjects: 501
Study 10534591 — intervention group
Group type: EXPERIMENTAL
Intervention: COOP charts
Number of subjects: 129
Study 10534591 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 129
Study 7781462 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg/hr L-arginine
Number of subjects: 21
Study 7781462 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg erythromycin
Number of subjects: 21
Study 7781462 — intervention group
Group type: COMPARATOR
Intervention: Liquid meal
Number of subjects: 21